About this trial

This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acute recurrent pancreatitis and chronic pancreatitis may help identify patients who are at risk of pancreatic cancer.

Eligibility criteria

Qualifiers

All subjects/parents must sign an informed consent and/or assent indicating that they are aware of the investigational nature of this study

Subjects/parents must have signed an authorization for the release of their or their child's protected health information

All children must be under 18 years of age at the time of enrollment

Abdominal pain compatible with AP

Disqualifiers

Subjects must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the subject's ability to tolerate study interventions

Trial design

Treatments tested in this trial

  • Biospecimen Collection
  • Quality-of-Life Assessment
  • Questionnaire Administration

Treatment groups

1,600 Participants
are divided into 1 treatment group

Locations

26
Australia
Sydney Children's Hospital2031, RandwickNew South Wales, Australia
Canada
Hospital for Sick ChildrenM5G 1X8, TorontoOntario, Canada
The Montreal Children's Hospital of the MUHCH3H 1P3, MontrealQuebec, Canada
Israel
Hadassah University Hospital91120, Jerusalem Israel

Sponsors and collaborators

M.D. Anderson Cancer Center

Lead sponsor

National Cancer Institute (NCI)

Collaborator